Thymoquinone protects against experimental colitis in rats

Toxicology Letters

Volumn 143, Issue 2, 2003, Pages 133-143

  Mahgoub, Afaf A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Acetic acid colitis; Protective effects; Rats; Thymoquinone

Indexed keywords

ACETIC ACID; GLUTATHIONE; HISTAMINE; MYELOPEROXIDASE; SALAZOSULFAPYRIDINE; THROMBOCYTE ACTIVATING FACTOR; THYMOQUINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; COLITIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; ENZYME ACTIVITY; ENZYME ASSAY; HISTOPATHOLOGY; LOW DRUG DOSE; MALE; NONHUMAN; PARAMETER; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN DETERMINATION; RAT;

EID: 0037718199     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(03)00173-5     Document Type: Article

References (39)

1. Ahnfelt-Ronn I., Nielsen O.H., Christensen A., Langholz E., Binder V., Riis P. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology. 98:1990;1162-1169.
2. Aihara H., Hiwatashi N. Salazosulfapyridine and 5-aminosalicylic acid agents. Nippon Rinsho. 57:1999;247-250.
3. Almer S., Kald B., Franzen L. Concentration of platelet activating factor in rectal mucosa in patients with ulcerative colitis. Eur. J. Surg. 5:1996;319-396.
4. Babbs C.F. Oxygen radicals in ulcerative colitis. Free Radic. Biol. Med. 13:1992;169-181.
5. Bradley P.P., Friebal D.A., Christensen R.D. Measurements of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J. Invest. Dermatol. 78:1982;206-209.
6. Chakravarty N. Inhibition of histamine release from mast cells by Nigellone. Ann. Allergy. 70:1993;237-242.
7. Choudhary S., Keshavarzian A., Yong S., Wade M., Boeckino S., Day B.J., Banan A. A novel antioxidant zolimid and AEOL11201 ameliorate colitis in rats. Dig. Dis. Sci. 46:2001;2222-2230.
8. Daba M.H., Abdel-Rahman M.S. Hepatoprotective activity of thymoquinone in isolated rat hepatocytes. Toxicol. Lett. 95:1998;23.
9. Dagali U., Balk M., Yacel D., Ulker A., Over H., Saydam G., Sahin B. The role of reactive oxygen metabolites in ulcerative colitis. Inflamm. Bow. Dis. 3:1997;260-264.
10. El-Dakhakhny M. Studies on the chemical constitution of Egyptian Nigella sativa L. seeds II. The essential oil. Planta Med. 11:1963;465-470.
11. El-Dakhakhny M. Studies on the Egyptian Nigella sativa L. part IV: some pharmacological properties of seed's active priniciple in comparison to its dihydro compounds and its polymer. Arzneim.-Forsch. 15:1965;1227-1229.
12. Eliakim R., Karmeli F., Razin E., Rachmilewitz D. Role of platelet activating factor in ulcerative colitis enhanced production during active disease and inhibition by sulfasalazin and prednisolone. Gestroenterology. 95:1988;1167-1172.
13. Fox C.C., Lazenby A.J., Moore W.C., Yardley J.H., Bayless T.M., Lichtenstein M.L. Enhancement of human intestinal mast cell mediator release in active ulcerative colitis. Gastroenterology. 99:1990;119-124.
14. Gionchetti P., Guarnieri G., Campieri M., Belluzzi A., Brignola C., Iannone P., Miglioli M., Barbara L. Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig. Dis. Sci. 36:1991;174-178.
15. Grisham M.B. Oxidants and free radicals in inflammatory bowel disease. Lancet. 344:1994;851-861.
16. Houghton P.J., Zarka R., Heras B.D.L., Hoult J.R. Fixed oil of Nigella sativa and derived thymoquinone inhibit eicosanoid generation in leukocytes and membrane lipid peroxidation. Planta Med. 61:1995;33-36.
17. Karmeli F., Cohen P., Rachmi Lewitz D. Cyclooxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats. Eur. J. Gastroenterol. Hepatol. 12:2000;223-231.
18. Keshavarzian A., Morgan G., Sedghi S., Doria M. Role of reactive oxygen metabolites in experimental colitis. Gut. 31:1990;786-790.
19. Keshavarzian A., Sedghi S., Kanofsky J., List T., Robinson C., Ibrahim C. Excessive production of reactive oxygen metabolites by inflammed colon: analysis by chemiluminescence probe. Gastroenterology. 103:1992;117-185.
20. Knutson L., Ahrenstedt O., Odlind B., Hallgren R. The jejunal secretion of histamine is increased in active Crohn's disease. Gastroenterology. 98:1990;849-854.
21. Kolios G., Petoumenos C., Nakos A. Mediators of inflammation: production and implication in inflammatory bowel disease. Hepato-Gastroenteology. 45:1998;1601-1609.
22. Lorenz W., Barth H., Kushe J. Histamine in the pig: determination, distribution, release and pharmacological actions. Eur. J. Pharmacol. 14:1971;155-175.
23. Mahfouz M., Abdel-Muguid R., El-Dakhakhny M. The effect of Nigellone-therapy on the histaminopexic power of the blood sera of asthmatic patients. Arzneim.-Forsch. 15:1965;1230-1234.
24. Martensson J., Jain A., Meister A. Glutathione is required for intestinal function. Proc. Natl. Acad. Sci. USA. 87:1990;1715-1719.
25. Meister A. Glutathione-ascorbic acid antioxidant system in animals. J. Biol. Chem. 269:1994;9397-9400.
26. Millar A.D., Rampton D.S., Chander C.L., Claxson A.W.D., Blades S., Coumbe A., Panetta J., Morris C.J., Blake D.R. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut. 39:1996;407-415.
27. Miyachi Y., Yoshioko A., Imamura S., Niwa Y. Effect of sulfasalazine and its metabolites on the generation of reactive oxygen species. Gut. 28:1987;190-195.
28. Nagi M., Alam M.N., Badary K. Thymoquinone protects against carbon tetrachloride hepatotoxicity in mice via antioxidant mechanism. Biochem. Mol. Biol. Int. 47:1999;153.
29. Owens C.W.J., Belcher R.V. A colorimetric micro method for determination of glutathione. Biochem. J. 94:1965;705-711.
30. Raithel M., Matek M., Baenkler H.W., Jorde W., Hahn E. Mucosal histamine content and histamine secretion in Crohn's disease, ulcerative colitis and allergic enteropathy. Int. Arch. Allergy Immunol. 108:1995;127-133.
31. Sanahan F. Pathogenesis of ulcerative colitis. Lancet. 342:1993;407-411.
32. 2 and leukotriene B in isolated colonic mucosal cells. Curr. Med. Res. Opin. 13:1996;417-425.
33. Sharon P., Stenson W.F. Metabolism of arachidonic acid in acetic acid colitis in rats. Gastroenterology. 88:1985;55-63.
34. Thompson H., Buchman P. Mast cell population in rectal biopsies from patients with Crohn's disease. Pepys J., Edwards A.M. The Mast Cell. Its Role in Health and Disease. 1979;697-701 Pitman, London.
35. Wallace J.L., Braquet P., Ibboston G.C. Assessment of the role of platelet activating factor in an animal model of inflammatory bowel disease. J. Lipid Med. 1:1989;13-23.
36. Will P.C., Thomas T.K., Inverson L. Platelet activating factor as a proinflammatory medicator in acetic acid-induced colitis in the rat. Agents Actions. 34:1991;181-184.
37. Williams J.G., Hallett M.B. Effect of sulfasalazine and its active metabolite, 5-aminosalicylic acid, on toxic metabolite production by neutrophils. Gut. 30:1989;1581-1587.
38. Yavuz T., Yuksel M., Yegen B.C., Alican I. The effect of antioxidant therapy on colonic inflammation in the rat. Res. Exp. Med. 199:1999;101-110.
39. Yue G., Sun F.F., Dunn C., Yin K., Wong P.Y.K. The 21-aminosteroid trilazad mesylate can ameliorate inflammatory bowel disease in rats. J. Pharmacol. Exp. Ther. 276:1996;265-270.